Signos, headquartered in United States, remains privately held in the healthtech / diabetes space. Investors last valued the company at $1B (post-money). No public ticker exists for the company.
1 valuation. The latest, $1B post-money, was set by the Series C+ in May 2026.
GVLEAD
GVLEAD
DexcomLEADBBlue Cross Blue ShieldLEAD
General Catalyst
Accel PartnersGVGVDexcomSignos operates a metabolic health platform that pairs an off-the-shelf continuous glucose monitor from Dexcom with an AI-powered app, letting users see how food, exercise, and daily habits affect their glucose levels. Co-founder and CEO Sharam Fouladgar-Mercer built the company around the idea that stabilizing glucose supports sustainable weight management.
In August 2025 the FDA approved Signos as the first glucose monitoring system specifically cleared for weight management, opening it to any patient without a prescription requirement. Customers can choose three-month or six-month plans, priced at $139 and $129 respectively, and the system can be used alongside GLP-1 medications or after bariatric surgery.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Signos.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Signos availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Signos included.
The last valuation is $1B (post-money, May 2026).
Lead investors for each round are in the funding timeline.
The closest healthtech / diabetes peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
